APO Research
Talk to an analyst

APO RESEARCH · REPORT

Secondary Progressive Multiple Sclerosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Secondary Progressive Multiple Sclerosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025197 pages

Choose your research edition.

Industry ResearchSecondary Progressive Multiple Sclerosis Drug Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Secondary Progressive Multiple Sclerosis Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Secondary Progressive Multiple Sclerosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Secondary Progressive Multiple Sclerosis Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Secondary Progressive Multiple Sclerosis Drug Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Secondary Progressive Multiple Sclerosis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Secondary Progressive Multiple Sclerosis Drug include AB Science SA, Actelion Ltd, F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc., Immune Response BioPharma, Inc., Innate Immunotherapeutics Ltd, Kyorin Pharmaceutical Co., Ltd. and Mallinckrodt Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Secondary Progressive Multiple Sclerosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Secondary Progressive Multiple Sclerosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Secondary Progressive Multiple Sclerosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Secondary Progressive Multiple Sclerosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Secondary Progressive Multiple Sclerosis Drug Segment by Company

AB Science SA

Actelion Ltd

F. Hoffmann-La Roche Ltd.

Genzyme Corporation

Glialogix, Inc.

Immune Response BioPharma, Inc.

Innate Immunotherapeutics Ltd

Kyorin Pharmaceutical Co., Ltd.

Mallinckrodt Plc

MedDay SA

MedImmune, LLC

Merck KGaA

Meta-IQ ApS

Opexa Therapeutics, Inc.

Xenetic Biosciences (UK) Limited

Biogen, Inc.

Novartis AG

Secondary Progressive Multiple Sclerosis Drug Segment by Type

Etomoxir

Inebilizumab

IB-MS

GLX-1112

DC-TAB

Others

Secondary Progressive Multiple Sclerosis Drug Segment by Application

Hospital

Clinic

Others

Secondary Progressive Multiple Sclerosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Secondary Progressive Multiple Sclerosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Secondary Progressive Multiple Sclerosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Secondary Progressive Multiple Sclerosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Secondary Progressive Multiple Sclerosis Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Secondary Progressive Multiple Sclerosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Secondary Progressive Multiple Sclerosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Secondary Progressive Multiple Sclerosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Secondary Progressive Multiple Sclerosis Drug Industry Trends Table 2. Secondary Progressive Multiple Sclerosis Drug Industry Drivers Table 3. Secondary Progressive Multiple Sclerosis Drug Industry Opportunities and Challenges Table 4. Secondary Progressive Multiple Sclerosis Drug Industry Restraints Table 5. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Manufacturers Table 9. Global Secondary Progressive Multiple Sclerosis Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Secondary Progressive Multiple Sclerosis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Secondary Progressive Multiple Sclerosis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Secondary Progressive Multiple Sclerosis Drug Manufacturers, Product Type & Application Table 13. Global Secondary Progressive Multiple Sclerosis Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Secondary Progressive Multiple Sclerosis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Etomoxir Table 17. Major Manufacturers of Inebilizumab Table 18. Major Manufacturers of IB-MS Table 19. Major Manufacturers of GLX-1112 Table 20. Major Manufacturers of DC-TAB Table 21. Major Manufacturers of Others Table 22. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 24. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2027-2032) & (K Units) Table 25. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2021-2026) Table 26. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2027-2032) Table 27. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2026) & (K Units) Table 29. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2027-2032) & (K Units) Table 30. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2021-2026) Table 31. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Others Table 35. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 37. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2027-2032) & (K Units) Table 38. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2021-2026) Table 39. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2027-2032) Table 40. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2026) & (K Units) Table 42. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2027-2032) & (K Units) Table 43. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2021-2026) Table 44. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2027-2032) Table 45. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2021-2026) Table 48. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 52. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032) & (K Units) Table 53. Europe Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 55. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2021-2026) Table 66. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2027-2032) Table 67. AB Science SA Company Information Table 68. AB Science SA Business Overview Table 69. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 71. AB Science SA Recent Development Table 72. Actelion Ltd Company Information Table 73. Actelion Ltd Business Overview Table 74. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 76. Actelion Ltd Recent Development Table 77. F. Hoffmann-La Roche Ltd. Company Information Table 78. F. Hoffmann-La Roche Ltd. Business Overview Table 79. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 81. F. Hoffmann-La Roche Ltd. Recent Development Table 82. Genzyme Corporation Company Information Table 83. Genzyme Corporation Business Overview Table 84. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 86. Genzyme Corporation Recent Development Table 87. Glialogix, Inc. Company Information Table 88. Glialogix, Inc. Business Overview Table 89. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 91. Glialogix, Inc. Recent Development Table 92. Immune Response BioPharma, Inc. Company Information Table 93. Immune Response BioPharma, Inc. Business Overview Table 94. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 96. Immune Response BioPharma, Inc. Recent Development Table 97. Innate Immunotherapeutics Ltd Company Information Table 98. Innate Immunotherapeutics Ltd Business Overview Table 99. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 101. Innate Immunotherapeutics Ltd Recent Development Table 102. Kyorin Pharmaceutical Co., Ltd. Company Information Table 103. Kyorin Pharmaceutical Co., Ltd. Business Overview Table 104. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 106. Kyorin Pharmaceutical Co., Ltd. Recent Development Table 107. Mallinckrodt Plc Company Information Table 108. Mallinckrodt Plc Business Overview Table 109. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 111. Mallinckrodt Plc Recent Development Table 112. MedDay SA Company Information Table 113. MedDay SA Business Overview Table 114. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 116. MedDay SA Recent Development Table 117. MedImmune, LLC Company Information Table 118. MedImmune, LLC Business Overview Table 119. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 121. MedImmune, LLC Recent Development Table 122. Merck KGaA Company Information Table 123. Merck KGaA Business Overview Table 124. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 126. Merck KGaA Recent Development Table 127. Meta-IQ ApS Company Information Table 128. Meta-IQ ApS Business Overview Table 129. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 131. Meta-IQ ApS Recent Development Table 132. Opexa Therapeutics, Inc. Company Information Table 133. Opexa Therapeutics, Inc. Business Overview Table 134. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 136. Opexa Therapeutics, Inc. Recent Development Table 137. Xenetic Biosciences (UK) Limited Company Information Table 138. Xenetic Biosciences (UK) Limited Business Overview Table 139. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 141. Xenetic Biosciences (UK) Limited Recent Development Table 142. Biogen, Inc. Company Information Table 143. Biogen, Inc. Business Overview Table 144. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 146. Biogen, Inc. Recent Development Table 147. Novartis AG Company Information Table 148. Novartis AG Business Overview Table 149. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 151. Novartis AG Recent Development Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Secondary Progressive Multiple Sclerosis Drug Distributors List Table 155. Secondary Progressive Multiple Sclerosis Drug Customers List Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Secondary Progressive Multiple Sclerosis Drug Product Image Figure 2. Global Secondary Progressive Multiple Sclerosis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Secondary Progressive Multiple Sclerosis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Secondary Progressive Multiple Sclerosis Drug Sales (2021-2032) & (K Units) Figure 5. Global Secondary Progressive Multiple Sclerosis Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Secondary Progressive Multiple Sclerosis Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Etomoxir Image Figure 9. Inebilizumab Image Figure 10. IB-MS Image Figure 11. GLX-1112 Image Figure 12. DC-TAB Image Figure 13. Others Image Figure 14. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2021-2032) Figure 17. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2021-2032) Figure 26. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2021-2032) Figure 43. China Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Secondary Progressive Multiple Sclerosis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Secondary Progressive Multiple Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Secondary Progressive Multiple Sclerosis Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Secondary Progressive Multiple Sclerosis Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Etomoxir
  • Inebilizumab
  • IB-MS
  • GLX-1112
  • DC-TAB
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • AB Science SA
  • Actelion Ltd
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Glialogix, Inc.
  • Immune Response BioPharma, Inc.
  • Innate Immunotherapeutics Ltd
  • Kyorin Pharmaceutical Co., Ltd.
  • Mallinckrodt Plc
  • MedDay SA
  • MedImmune, LLC
  • Merck KGaA
  • Meta-IQ ApS
  • Opexa Therapeutics, Inc.
  • Xenetic Biosciences (UK) Limited
  • Biogen, Inc.
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Secondary Progressive Multiple Sclerosis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Secondary Progressive Multiple Sclerosis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Secondary Progressive Multiple Sclerosis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Secondary Progressive Multiple Sclerosis Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Secondary Progressive Multiple Sclerosis Drug Market Dynamics
  1. 2.1 Secondary Progressive Multiple Sclerosis Drug Industry Trends
  2. 2.2 Secondary Progressive Multiple Sclerosis Drug Industry Drivers
  3. 2.3 Secondary Progressive Multiple Sclerosis Drug Industry Opportunities and Challenges
  4. 2.4 Secondary Progressive Multiple Sclerosis Drug Industry Restraints
3 Secondary Progressive Multiple Sclerosis Drug Market by Manufacturers
  1. 3.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Secondary Progressive Multiple Sclerosis Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Secondary Progressive Multiple Sclerosis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Secondary Progressive Multiple Sclerosis Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Secondary Progressive Multiple Sclerosis Drug Manufacturers, Product Type & Application
  7. 3.7 Global Secondary Progressive Multiple Sclerosis Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Secondary Progressive Multiple Sclerosis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Secondary Progressive Multiple Sclerosis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Secondary Progressive Multiple Sclerosis Drug Tier 1, Tier 2, and Tier 3
4 Secondary Progressive Multiple Sclerosis Drug Market by Type
  1. 4.1 Secondary Progressive Multiple Sclerosis Drug Type Introduction
  2. 4.1.1 Etomoxir
  3. 4.1.2 Inebilizumab
  4. 4.1.3 IB-MS
  5. 4.1.4 GLX-1112
  6. 4.1.5 DC-TAB
  7. 4.1.6 Others
  8. 4.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Type
  9. 4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type
  13. 4.3.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2021-2032)
5 Secondary Progressive Multiple Sclerosis Drug Market by Application
  1. 5.1 Secondary Progressive Multiple Sclerosis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Application
  6. 5.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application
  10. 5.3.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2021-2032)
6 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region
  1. 6.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region
  1. 7.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region
  2. 7.1.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032)
  8. 7.2.2 North America Secondary Progressive Multiple Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032)
  11. 7.3.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AB Science SA
  2. 8.1.1 AB Science SA Company Information
  3. 8.1.2 AB Science SA Business Overview
  4. 8.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  6. 8.1.5 AB Science SA Recent Developments
  7. 8.2 Actelion Ltd
  8. 8.2.1 Actelion Ltd Company Information
  9. 8.2.2 Actelion Ltd Business Overview
  10. 8.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  12. 8.2.5 Actelion Ltd Recent Developments
  13. 8.3 F. Hoffmann-La Roche Ltd.
  14. 8.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 8.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 8.3.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  18. 8.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 8.4 Genzyme Corporation
  20. 8.4.1 Genzyme Corporation Company Information
  21. 8.4.2 Genzyme Corporation Business Overview
  22. 8.4.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  24. 8.4.5 Genzyme Corporation Recent Developments
  25. 8.5 Glialogix, Inc.
  26. 8.5.1 Glialogix, Inc. Company Information
  27. 8.5.2 Glialogix, Inc. Business Overview
  28. 8.5.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  30. 8.5.5 Glialogix, Inc. Recent Developments
  31. 8.6 Immune Response BioPharma, Inc.
  32. 8.6.1 Immune Response BioPharma, Inc. Company Information
  33. 8.6.2 Immune Response BioPharma, Inc. Business Overview
  34. 8.6.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  36. 8.6.5 Immune Response BioPharma, Inc. Recent Developments
  37. 8.7 Innate Immunotherapeutics Ltd
  38. 8.7.1 Innate Immunotherapeutics Ltd Company Information
  39. 8.7.2 Innate Immunotherapeutics Ltd Business Overview
  40. 8.7.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  42. 8.7.5 Innate Immunotherapeutics Ltd Recent Developments
  43. 8.8 Kyorin Pharmaceutical Co., Ltd.
  44. 8.8.1 Kyorin Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Kyorin Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  48. 8.8.5 Kyorin Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Mallinckrodt Plc
  50. 8.9.1 Mallinckrodt Plc Company Information
  51. 8.9.2 Mallinckrodt Plc Business Overview
  52. 8.9.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  54. 8.9.5 Mallinckrodt Plc Recent Developments
  55. 8.10 MedDay SA
  56. 8.10.1 MedDay SA Company Information
  57. 8.10.2 MedDay SA Business Overview
  58. 8.10.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  60. 8.10.5 MedDay SA Recent Developments
  61. 8.11 MedImmune, LLC
  62. 8.11.1 MedImmune, LLC Company Information
  63. 8.11.2 MedImmune, LLC Business Overview
  64. 8.11.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  66. 8.11.5 MedImmune, LLC Recent Developments
  67. 8.12 Merck KGaA
  68. 8.12.1 Merck KGaA Company Information
  69. 8.12.2 Merck KGaA Business Overview
  70. 8.12.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  72. 8.12.5 Merck KGaA Recent Developments
  73. 8.13 Meta-IQ ApS
  74. 8.13.1 Meta-IQ ApS Company Information
  75. 8.13.2 Meta-IQ ApS Business Overview
  76. 8.13.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  78. 8.13.5 Meta-IQ ApS Recent Developments
  79. 8.14 Opexa Therapeutics, Inc.
  80. 8.14.1 Opexa Therapeutics, Inc. Company Information
  81. 8.14.2 Opexa Therapeutics, Inc. Business Overview
  82. 8.14.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  84. 8.14.5 Opexa Therapeutics, Inc. Recent Developments
  85. 8.15 Xenetic Biosciences (UK) Limited
  86. 8.15.1 Xenetic Biosciences (UK) Limited Company Information
  87. 8.15.2 Xenetic Biosciences (UK) Limited Business Overview
  88. 8.15.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  90. 8.15.5 Xenetic Biosciences (UK) Limited Recent Developments
  91. 8.16 Biogen, Inc.
  92. 8.16.1 Biogen, Inc. Company Information
  93. 8.16.2 Biogen, Inc. Business Overview
  94. 8.16.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  96. 8.16.5 Biogen, Inc. Recent Developments
  97. 8.17 Novartis AG
  98. 8.17.1 Novartis AG Company Information
  99. 8.17.2 Novartis AG Business Overview
  100. 8.17.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  102. 8.17.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Secondary Progressive Multiple Sclerosis Drug Value Chain Analysis
  2. 9.1.1 Secondary Progressive Multiple Sclerosis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Secondary Progressive Multiple Sclerosis Drug Production Mode & Process
  6. 9.2 Secondary Progressive Multiple Sclerosis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Secondary Progressive Multiple Sclerosis Drug Distributors
  9. 9.2.3 Secondary Progressive Multiple Sclerosis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst